Zobrazeno 1 - 10 of 63 pro vyhledávání: '"Pg, Sleph"'
1
Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity
Autor: Gj, Grover, Alonzo Aj, D., Keith Garlid, Bajgar R, Nj, Lodge, Pg, Sleph, Rb, Darbenzio, Ta, Hess, Ma, Smith, Paucek P, Ks, Atwal
Publikováno v: Europe PubMed Central
Previous work described ATP-sensitive K(+) channel (K(ATP)) openers (e.g., BMS-180448), which retain the cardioprotective activity of agents such as cromakalim while being significantly less potent as vasodilators. In this study, we describe the phar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::28d1728cd9b141566b2813444eaa1c4c
https://pubmed.ncbi.nlm.nih.gov/11356945
Zobrazit plný text záznamu
2
Akademický článek
Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.
Autor: Finlay HJ; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Jiang J; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Rampulla R; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Salvati ME; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Qiao JX; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Wang TC; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Lawrence RM; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Harikrishnan LS; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Kamau MG; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Taylor DS; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Chen AYA; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Yin X; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Huang CS; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Chang M; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Chen XQ; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Sleph PG; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Xu C; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Li J; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Levesque P; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Adam LP; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States., Wexler RR; Departments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2019 May 06; Vol. 10 (6), pp. 911-916. Date of Electronic Publication: 2019 May 06 (Print Publication: 2019).
Zobrazit plný text záznamu
3
Akademický článek
PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor.
Autor: Hangeland JJ; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Abell LM; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Adam LP; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Jiang J; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Friends TJ; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Haque LE; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Neels J; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Onorato JM; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Chen AYA; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Taylor DS; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Yin X; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Harrity TW; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Basso MD; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Yang R; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Sleph PG; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Gordon DA; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Huang CS; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Wexler RR; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Finlay HJ; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States., Lawrence RM; Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Jun 15; Vol. 9 (7), pp. 673-678. Date of Electronic Publication: 2018 Jun 15 (Print Publication: 2018).
Zobrazit plný text záznamu
4
Akademický článek
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
Autor: Qiao JX; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Wang TC; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Adam LP; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Chen AY; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Taylor DS; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Yang RZ; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Zhuang S; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Sleph PG; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Li JP; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Li D; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Yin X; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Chang M; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Chen XQ; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Shen H; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Li J; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Smith D; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Wu DR; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Leith L; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Harikrishnan LS; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Kamau MG; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Miller MM; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Bilder D; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Rampulla R; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Li YX; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Xu C; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Lawrence RM; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Poss MA; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Levesque P; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Gordon DA; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Huang CS; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Finlay HJ; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Wexler RR; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States., Salvati ME; Departments of †Discovery Chemistry, ‡Discovery Biology, §Discovery Toxicology, ∥Preclinical Candidate Optimization, and ⊥Pharmaceutics, Bristol-Myers Squibb Company, Research and Development , P.O. Box 4000, Princeton, New Jersey 08543-4000, United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2015 Nov 25; Vol. 58 (22), pp. 9010-26. Date of Electronic Publication: 2015 Nov 17.
Zobrazit plný text záznamu
5
Akademický článek
Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.
Autor: Wang Y; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA. Electronic address: yufeng.wang@bms.com., Yang W; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Finlay HJ; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Harikrishnan LS; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Jiang J; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Kamau MG; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Van Kirk K; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Nirschl DS; Synthesis & Analysis Technology Team, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Taylor DS; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Chen AY; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Yin X; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Sleph PG; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Yang RZ; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Huang CS; Department of Preclinical Candidate Optimization, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Adam LP; Department of Biology, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Lawrence RM; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Wexler RR; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA., Salvati ME; Department of Chemistry, Bristol-Myers Squibb, PO Box 4000, Princeton, NJ 08543-4000, USA.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2014 Feb 01; Vol. 24 (3), pp. 860-4. Date of Electronic Publication: 2014 Jan 06.
Zobrazit plný text záznamu
6
Akademický článek
Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
Autor: Harikrishnan LS; Department of Chemistry, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, USA. Lalgudi.Harikrishnan@bms.com, Finlay HJ, Qiao JX, Kamau MG, Jiang J, Wang TC, Li J, Cooper CB, Poss MA, Adam LP, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Sitkoff DF, Galella MA, Nirschl DS, Van Kirk K, Miller AV, Huang CS, Chang M, Chen XQ, Salvati ME, Wexler RR, Lawrence RM
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2012 Jul 12; Vol. 55 (13), pp. 6162-75. Date of Electronic Publication: 2012 Jun 22.
Zobrazit plný text záznamu
7
Akademický článek
N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.
Autor: Nirschl AA; Discovery Chemistry, Analytical Research & Development, Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA., Zou Y, Krystek SR Jr, Sutton JC, Simpkins LM, Lupisella JA, Kuhns JE, Seethala R, Golla R, Sleph PG, Beehler BC, Grover GJ, Egan D, Fura A, Vyas VP, Li YX, Sack JS, Kish KF, An Y, Bryson JA, Gougoutas JZ, DiMarco J, Zahler R, Ostrowski J, Hamann LG
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2009 May 14; Vol. 52 (9), pp. 2794-8.
Zobrazit plný text záznamu
8
Akademický článek
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.
Autor: Manfredi MC; Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-4000, USA. mark.manfredi@bms.com, Bi Y, Nirschl AA, Sutton JC, Seethala R, Golla R, Beehler BC, Sleph PG, Grover GJ, Ostrowski J, Hamann LG
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2007 Aug 15; Vol. 17 (16), pp. 4487-90. Date of Electronic Publication: 2007 Jun 06.
Zobrazit plný text záznamu
9
Akademický článek
Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.
Autor: Li JJ; Discovery Chemistry, Computer Assisted Drug Design, Metabolic Disease Research, Metabolism and Pharmacokinetics, Discovery Analytical Sciences, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-5400, USA. James.Li@bms.com, Sutton JC, Nirschl A, Zou Y, Wang H, Sun C, Pi Z, Johnson R, Krystek SR Jr, Seethala R, Golla R, Sleph PG, Beehler BC, Grover GJ, Fura A, Vyas VP, Li CY, Gougoutas JZ, Galella MA, Zahler R, Ostrowski J, Hamann LG
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2007 Jun 28; Vol. 50 (13), pp. 3015-25. Date of Electronic Publication: 2007 Jun 07.
Zobrazit plný text záznamu
10
Akademický článek
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
Autor: Ostrowski J; Department of Metabolic Diseases, Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, NJ 08543, USA., Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG
Publikováno v: Endocrinology [Endocrinology] 2007 Jan; Vol. 148 (1), pp. 4-12. Date of Electronic Publication: 2006 Sep 28.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje